NanoVibronix, Inc. (NAOV) Bundle
A Brief History of NanoVibronix, Inc. (NAOV)
Company Overview
NanoVibronix, Inc. was founded in 2000 and operates in the medical device industry, focusing on ultrasound technology for therapeutic applications. The company is publicly traded under the ticker symbol NAOV.
Key Developments
- 2001: Initial product concept development.
- 2006: Received FDA clearance for its first product, PainShield.
- 2013: Launch of the UroShield system aimed at reducing catheter-related infection.
- 2019: Acquired a patent for a novel delivery system for ultrasound therapy.
- 2020: Expansion into the European market with CE marking for PainShield.
Financial Performance
As of Q3 2023, NanoVibronix, Inc. reported total revenues of $2.1 million for the fiscal year ended December 31, 2022.
For the same fiscal year, the company reported a net loss of $3.6 million, with a loss per share of $0.21.
Recent Milestones
In July 2023, NanoVibronix announced a strategic partnership with a leading healthcare provider to enhance market penetration for its UroShield product.
Stock Performance
The stock price of NAOV as of October 2023 was approximately $1.45.
The market capitalization was around $40 million.
Product Portfolio
| Product Name | Launch Year | Primary Indication | Current Status |
|---|---|---|---|
| PainShield | 2006 | Chronic Pain Relief | Commercially Available |
| UroShield | 2013 | Catheter-Associated Infection Prevention | Commercially Available |
| WoundShield | 2022 | Wound Healing | In Development |
Market Position
The market for non-invasive ultrasound therapy is projected to reach $9 billion by 2025, with a CAGR of 6.9% from 2020 to 2025. NanoVibronix's advancements place it favorably within this growing sector.
Research and Development
For 2023, NanoVibronix allocated approximately $800,000 towards R&D initiatives aimed at the development of next-generation ultrasound devices.
Regulatory Approvals
- FDA 510(k) Clearance for PainShield - 2006
- CE Marking for UroShield - 2020
- FDA Breakthrough Device Designation for WoundShield - 2023
Strategic Partnerships
- Partnership with University of California, San Diego for clinical trials - 2021
- Collaboration with healthcare providers for UroShield rollout - 2023
A Who Owns NanoVibronix, Inc. (NAOV)
Company Overview
NanoVibronix, Inc. (NAOV) is engaged in the development and commercialization of non-invasive therapeutic ultrasound products. The company specializes in medical devices that enhance healing through the application of ultrasound technology.
Shareholder Structure
As of the latest reporting, NanoVibronix, Inc. has a diverse shareholder base comprising institutional investors, private investors, and company executives. Below is a breakdown of ownership percentages:
| Shareholder Type | Percentage Ownership |
|---|---|
| Institutional Investors | 25% |
| Company Executives and Directors | 15% |
| Retail Investors | 60% |
Major Institutional Shareholders
The following institutions hold significant stakes in NanoVibronix, Inc.:
| Institution | Shares Held | Percentage of Total Shares |
|---|---|---|
| The Vanguard Group, Inc. | 1,200,000 | 10% |
| BlackRock, Inc. | 900,000 | 7.5% |
| Wellington Management Company, LLP | 800,000 | 6.5% |
Executive Leadership Ownership
Key executives of NanoVibronix, Inc. maintain a substantial ownership stake in the company:
| Name | Position | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| David W. Fink | CEO | 500,000 | 4% |
| Michael A. Nascimento | CFO | 300,000 | 2.5% |
| John Doe | CTO | 200,000 | 1.5% |
Recent Financial Performance
As of the latest quarterly report, NanoVibronix, Inc. reported the following financial metrics:
- Total Revenue: $3 million
- Net Loss: $1.5 million
- Cash and Cash Equivalents: $4 million
- Market Capitalization: $15 million
Stock Performance
The stock performance of NanoVibronix, Inc. has exhibited the following metrics over the past year:
- 52-Week High: $3.00
- 52-Week Low: $0.60
- Current Stock Price: $1.25
- Price-to-Earnings Ratio: N/A (Negative Earnings)
Conclusion
NanoVibronix, Inc. remains a company with a mix of institutional and retail investors, alongside a dedicated executive team holding significant shares. Its financial trajectory continues to evolve within the competitive landscape of medical technology.
NanoVibronix, Inc. (NAOV) Mission Statement
Company Overview
NanoVibronix, Inc. (NAOV) specializes in the development of innovative medical devices utilizing ultrasound technology. The company's mission revolves around enhancing patient care through non-invasive and innovative solutions.
Core Values
- Innovation: Commitment to cutting-edge technology.
- Integrity: Upholding high ethical standards in all business practices.
- Collaboration: Working together with healthcare providers to improve patient outcomes.
Financial Performance
As of Q2 2023, NanoVibronix reported the following key financial figures:
| Financial Metric | Q2 2023 Amount (in USD) |
|---|---|
| Revenue | 1.11 million |
| Net Income | (2.04 million) |
| Total Assets | 5.25 million |
| Total Liabilities | 2.12 million |
| Cash and Equivalents | 1.75 million |
Market Position
In 2023, NanoVibronix holds an emerging position in the medical device market with a focus on:
- Urology Solutions: Products targeting urinary conditions.
- Pain Management: Non-invasive therapies for chronic pain relief.
- Wound Care: Innovative treatments for wound healing.
Customer Commitment
The company strives to provide unparalleled service and support to its customers, aiming for a customer satisfaction rate of over 90%.
Future Goals
NanoVibronix has outlined strategic objectives to achieve by 2025:
- Expand Product Line: Introduce three new medical devices.
- Increase Revenue: Achieve a target of 5 million in annual revenue.
- Enhance R&D: Allocate 15% of revenue to research and development efforts.
Recent Developments
In 2023, the company successfully launched:
- UroShield: A new non-invasive device for urology applications.
- PainShield: A pain management device that utilizes ultrasound technology.
Investment and Funding
As of 2023, NanoVibronix has raised approximately 3.5 million through private placements and strategic partnerships to support ongoing development and operations.
Conclusion
While this section does not provide conclusions, it encapsulates the mission, values, financial outlook, and strategic direction of NanoVibronix, Inc., reflecting its commitment to enhancing healthcare through innovative technologies.
How NanoVibronix, Inc. (NAOV) Works
Overview of NanoVibronix, Inc.
Overview of NanoVibronix, Inc.
NanoVibronix, Inc. is a medical device company that specializes in the development and commercialization of portable ultrasound devices. The company’s flagship product, the PainShield, utilizes ultrasound technology to provide non-invasive pain relief.
Business Model
The business model of NanoVibronix focuses on:
- Direct sales to healthcare providers and patients
- Partnerships with medical institutions for clinical usage
- Research and development to enhance existing products and create new solutions
Market and Financial Data
As of October 2023, NanoVibronix, Inc. has reported the following financial data:
| Fiscal Year | Total Revenue ($) | Net Income ($) | Market Capitalization ($) | Stock Price ($) |
|---|---|---|---|---|
| 2022 | 1,500,000 | -2,500,000 | 25,000,000 | 1.40 |
| 2023 (Q2) | 750,000 | -1,200,000 | 30,000,000 | 1.15 |
Product Offerings
NanoVibronix, Inc. offers several key products including:
- PainShield: A portable ultrasound device for pain relief.
- UroShield: A device aimed at preventing urinary tract infections.
- WoundShield: An ultrasound device designed to promote wound healing.
Research and Development
The company invests significantly in R&D to innovate and improve its product offerings. As of 2023:
| Year | R&D Expenditure ($) | Number of Patents Filed | Clinical Trials Conducted |
|---|---|---|---|
| 2022 | 800,000 | 5 | 3 |
| 2023 | 1,000,000 | 4 | 2 |
Regulatory Approvals
NanoVibronix has obtained regulatory approvals for its devices from the following entities:
- U.S. Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- Health Canada
Sales and Distribution Channels
The sales strategy includes:
- Direct selling through online platforms
- Distribution agreements with medical supply companies
- Partnerships with hospitals and clinics
Recent Developments
Key recent developments for NanoVibronix, Inc. include:
| Date | Event | Description |
|---|---|---|
| May 2023 | New Product Launch | Introduction of enhanced PainShield with better battery life. |
| August 2023 | Partnership Agreement | Collaboration with a major hospital network for device pilot programs. |
Competitive Landscape
NanoVibronix competes with other medical device companies, including:
- Ultrasound Technologies, Inc.
- Therapeutic Innovations, LLC
- Pain Management Solutions, Corp.
How NanoVibronix, Inc. (NAOV) Makes Money
Product Overview
Product Overview
NanoVibronix, Inc. specializes in the development of therapeutic ultrasound products, primarily targeting pain relief and wound healing. The company’s main products include:
- UroShield
- PainShield
- WoundShield
Their products generate revenue through sales to healthcare professionals and partnerships with hospitals and clinics.
Revenue Streams
The key revenue streams for NanoVibronix can be categorized as follows:
- Direct Sales
- Partnerships and Licensing
- Government Contracts
- Research Grants
Financial Performance
As of the third quarter of 2023, NanoVibronix reported the following financial metrics:
| Financial Metric | Q3 2023 Amount (USD) |
|---|---|
| Total Revenue | $1.2 million |
| Net Income (Loss) | ($1.5 million) |
| Operating Expenses | $2.3 million |
| Cash on Hand | $1.8 million |
Market Opportunities
The market for therapeutic ultrasound is projected to grow, creating opportunities for revenue expansion. As of 2023, the estimated market size for ultrasound therapy is approximately:
| Market Segment | Market Size (USD) |
|---|---|
| Pain Management | $2.5 billion |
| Wound Care | $4.1 billion |
Sales Strategy
NanoVibronix employs a multi-faceted sales strategy that includes:
- Direct sales force
- Online marketing campaigns
- Trade shows and conferences
- Collaboration with medical professionals
Partnerships and Collaborations
The company's growth is supported through strategic partnerships. Notable collaborations include:
- University of California, San Diego for research
- Veterans Affairs (VA) for product testing
Challenges and Risks
NanoVibronix faces several challenges that could impact revenue, including:
- Market competition
- Regulatory hurdles
- Market penetration in non-U.S. regions
Future Projections
For the upcoming fiscal year, NanoVibronix projects a revenue increase of:
| Projection Metric | Estimated Amount (USD) |
|---|---|
| Total Projected Revenue | $2.5 million |
| Projected Net Income (Loss) | ($800,000) |
NanoVibronix, Inc. (NAOV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support